Journal of Pharmaceutical Policy and Practice

It has been more than 3 years since cases were first reported; the COVID-19 pandemic remains an acute global emergency. The pandemic appears to be in transition, but the risk of the emergence of new variants and future surges remains real, leading to uncertainties about how to prioritize for both global governments as well as pharmacists. Given the current global pandemic, the Journal of Pharmaceutical Policy and Practice would like to announce a Call for Papers for a special series on COVID-19.

The journal seeks works related to prevention, newer treatments, medicines safety, medicines quality and shortages, pharmaceutical policy and practice, pharmacists and pharmacy services, information, and dissemination, as well as technology aspects of COVID-19.

Submissions are welcome on the following topics:

• Pharmacists and pharmacy services
• The use and safety aspects of investigational medicines, including antivirals, antimalarials, chloroquine, hydroxychloroquine, and other medicines
• The importance of reliable, independent sources of information with regards to prevention, treatment, and medication use
• The role of technology and pharmacy services
• Pharmacists’ response to COVID-19, including prevention, mitigation, treatment, and the role of pharmacy services
• Medicine safety, quality, and shortages
• Country-specific case studies on pharmacy and COVID-19

Prof. Zaheer Babar comes with over two decades of working in academia in Universities in United Kingdom, New Zealand and Malaysia. A pharmacist by training and a PhD in pharmaceutical policy, Prof. Babar is the recipient of the prestigious “Research Excellence Award” from The University of Auckland in 2012. His research programme covers areas related to pharmaceutical policy and practice, encompassing access and affordability of medicines, quality use of medicines and pharmacoeconomics. He has a successful track record of attracting national and international funding in these areas of medicines policy.

Prof. Babar has active research linkages with the leading universities in Australia, Europe and in the Asia Pacific Region and has acted as a consultant for World Health Organization, Health Action International, International Union against Tuberculosis and Lung Disease, International Pharmaceutical Federation (FIP) and for the Pharmaceutical Management Agency of New Zealand. He is a reviewer of top tier health policy journals and of funding bodies including Australian National Health and Medical Research Council. Prof. Babar is the founding editor of Journal of Pharmaceutical Policy and Practice (www.joppp.org).

Prof. Babar declares no conflict of interest.

Instructions for AuthorsSubmit an Article